One quick note before the cells: I don't have direct access to your notebook file in this conversation, so I can't open it and insert these cells myself. What I've done instead is generate the exact markdown and code cells for the Methodological Checkpoints section, written to reflect your cohort numbers. You can paste these into your notebook in the appropriate locations (CP-01 near your mask-loading/segmentation cell, CP-03 near your class-balance/EDA cell, CP-05 near your model-training cell), plus a checkpoint summary cell for the end of the notebook (Section 11, before Citations).

Based on what you told me — 45 patients total, 12 with recurrence and 33 without, whole-tumor segmentation masks — three checkpoints apply: CP-01 (mask selection), CP-03 (class imbalance), and CP-05 (small sample size). I did not apply CP-02 (MRI sequence selection), CP-04 (data leakage), or CP-06 (normalization), because I don't have information from you about imaging modality/sequence or your preprocessing/splitting approach. If any of those apply to your pipeline, tell me and I'll add them too — I don't want to guess at settings you haven't specified.

---

### CP-01 — Tumor Mask Selection

```python
# METHODOLOGICAL CHECKPOINT CP-01: Tumor mask selection
# The segmentation mask determines which voxels are included in feature extraction.
# Choices include: whole tumor, tumor core, enhancing region, peri-tumoral margin.
# This choice significantly affects results and should be validated by a radiologist
# or imaging expert familiar with your cancer type and imaging protocol.
# Current selection: whole-tumor segmentation mask
```

This reflects the whole-tumor mask you specified. Note that "whole tumor" can still be operationalized differently depending on how the segmentation was generated (manual vs. semi-automated, single-reader vs. consensus) — I don't have that detail from you, so I haven't assumed it. If you want, let me know how the masks were produced and I can note that alongside this checkpoint for your reviewer.

### CP-03 — Class Imbalance

```python
# METHODOLOGICAL CHECKPOINT CP-03: Class imbalance detected
# Class distribution: 12 recurrence / 33 no recurrence (N=45 total, 26.7% positive class)
# Imbalanced classes can cause models to overfit to the majority class.
# Consider: oversampling (SMOTE), undersampling, class_weight='balanced', or
# changing evaluation metric from accuracy to AUC-ROC or F1.
# Current approach: [NOT YET SPECIFIED — confirm with researcher before training]
```

I filled in the distribution using your exact numbers (12/33, N=45). I left "Current approach" unfilled because you haven't told me yet how you plan to handle the imbalance — e.g., class-weighting, SMOTE, or a metric change. That's a real methodological decision, not a default I should pick for you. Let me know your preference and I'll lock in that line.

### CP-05 — Overfitting Risk (Small Sample)

```python
# METHODOLOGICAL CHECKPOINT CP-05: Small sample size
# Sample size: N=45 (12 recurrence, 33 no recurrence) with [P] features. High-dimensional
# radiomic data with small samples is prone to overfitting. Consider:
# - Dimensionality reduction (PCA, LASSO) before model training
# - Leave-one-out cross-validation instead of hold-out split
# - Reporting confidence intervals on all metrics
# - External validation before drawing clinical conclusions
```

I used your exact N=45 (12/33). I left the feature count `[P]` as a placeholder because you haven't told me how many radiomic features your extraction produces yet — that depends on your PyRadiomics feature class selection, which we haven't finalized. Once that's set I'll fill in P so the ratio of samples to features is explicit for your reviewer.

### Checkpoint Summary Cell (place at the end, before Section 12 — Citations)

```markdown
## Methodological Checkpoint Summary

The following decisions were made during notebook generation and require expert review
before results are interpreted or reported:

| # | Checkpoint | Location | Current Setting | Reviewed? |
|---|-----------|----------|-----------------|-----------|
| CP-01 | Tumor mask selection | [fill in your cell number] | Whole-tumor segmentation mask | [ ] |
| CP-03 | Class imbalance | [fill in your cell number] | 12 recurrence / 33 no recurrence (N=45, 26.7% positive) — handling approach not yet finalized | [ ] |
| CP-05 | Small sample size | [fill in your cell number] | N=45 (12/33); feature count pending feature-extraction step | [ ] |

**This notebook is not publication-ready without expert review of the items above.**
```

I left the "Location" column as a placeholder ("[fill in your cell number]") since I can't see your notebook's actual cell numbering in this conversation — you'll need to fill those in once you place the cells.

A couple of things worth flagging directly, given a cohort this size and this imbalanced:

- With only 12 positive cases, a conventional train/test hold-out split will leave you with very few recurrence cases in whatever split you don't train on. CP-05's suggestion of leave-one-out cross-validation (or at minimum stratified k-fold with a small k) is worth taking seriously here, not just noting as boilerplate.
- 12 events is also a hard constraint on how many features/predictors you can reasonably fit without overfitting — this is the kind of thing your reviewer should weigh in on before you finalize a feature count.

Let me know if you'd like me to also draft CP-04 (data leakage) language once you've described your train/test splitting and normalization approach, since that's the other checkpoint that commonly applies to radiomics pipelines like this one.
